Business
INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.
RA'ANANA, Israel, Aug. 9, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"),
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, Aug. 9, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the \"Company\" or \"Inspira Technologies\"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.\nThe Usability Study included U.S. healthcare professionals who participated in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.\nDagi Ben Noon, Inspira Technologies' Chief Executive Officer, stated: \"We are advancing with the INSPIRA ART100. We plan to take a position in disrupting the medical device industry with our high-grade technology.\"\nThe INSPIRA ART100 is an extracorporeal blood circulation medical device designed for cardiac and pulmonary support, by providing continuous enrichment of the blood with oxygen and carbon dioxide removal. The INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.\nAbout Inspira Technologies OXY B.H.N. Ltd.Inspira Technologies has a clear mission to revolutionize acute respiratory care through innovation. Our aim is to develop medical technologies and products that prevent the need for mechanical ventilation. Empowering breathing without lungs, the flagship INSPIRA™ ART500 is designed to boost blood oxygen saturation levels in a matter of minutes, even as the patient remains awake. We strive to deliver blood circulation technology alongside AI driven monitoring and analytics to create patient-centric and data-driven solutions that enhance patient outcome and improve hospital efficiency. Through our continuous efforts, we aim to reshape the future of extracorporeal treatments to create a better healthcare experience for patients around the world. The Company's products have not yet been tested or used in humans and have not been approved by any regulatory entity.\nFor more information, please visit our corporate website:https://inspira-technologies.com \nForward-Looking Statement DisclaimerThis press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the curr...